MorphoSys Strengthens Patent Position on its Core HuCAL Technology in Europe
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the European Patent Office has granted a European divisional patent stemming from MorphoSys’s base HuCAL (Human Combinatorial Antibody Library) patent family, providing extended protection for the Company’s core technology. The new patent (EP1143006) captures HuCAL’s modular design at the DNA level, providing solid product claim protection in Europe.
MorphoSys’s HuCAL libraries comprise highly diverse, fully human synthetic antibodies that are highly engineerable through their modular CDR design. Its most advanced marketed version, HuCAL PLATINUM, provides rapid access to fully human antibodies as research tools, diagnostics and therapeutics. A first European HuCAL patent, which is now complemented by the new patent, was issued by the European Patent Office in 2002. HuCAL patents have been granted in the United States, Australia and at the European Patent Office. In total, the Company is prosecuting about thirty different proprietary patent families worldwide, which comes in addition to approximately thirty patent families the Company is pursuing in cooperation with its partners.
“This new patent is a further example of the pioneering nature of our proprietary core technology, HuCAL, and provides us with another solid layer of protection in Europe. We will carry on with this process, continuing to build a strong intellectual property portfolio around HuCAL and our other antibody-related technologies,” commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
MorphoSys is a publicly traded biotechnology company focused on the generation of fully human antibodies as a means to discover and develop innovative antibody-based drugs against life-threatening diseases. MorphoSys’s goal is to establish HuCAL as the technology of choice for antibody generation in research, diagnostics and therapeutic applications. The Company currently has therapeutic and research alliances with the majority of the world’s largest pharmaceutical companies including Boehringer Ingelheim, Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within these partnerships, more than 50 therapeutic antibody programs are ongoing in which MorphoSys participates through exclusive license and milestones payments as well as royalties on any end products. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit has operations in Germany (Munich), the U.S. (Raleigh, NC) and U.K. (Oxford). For further information please visit http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.